← Back to Search

Cholinesterase Inhibitor

Echothiophate Iodide for the Prevention of Progression of Myopia

Phase 4
Waitlist Available
Led By Stephen A Mathias, MD, MPH
Research Sponsored by Danbury Eye Physicians & Surgeons, PC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights
All Individual Drugs Already Approved
Approved for 5 Other Conditions
Drug Has Already Been Approved
Pivotal Trial

Summary

This trial is testing if special eye drops can slow down or stop nearsightedness in children. The drops may help the eyes focus and align better, potentially preventing worsening vision. Low-dose atropine eye drops have been studied for their effectiveness in slowing the progression of myopia in children.

Eligible Conditions
  • Near-sightedness

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Refractive Errors
Secondary study objectives
Axial Length
Choroiditis

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Echothiophate IodideExperimental Treatment1 Intervention
Echothiophate Iodide 0.03% one drop to each eye three times per week for 18 weeks
Group II: Carboxymethylcellulose Sodium (0.5%)Placebo Group1 Intervention
Carboxymethylcellulose Sodium (0.5%) one drop to each eye three times per week for 18 weeks

Find a Location

Who is running the clinical trial?

Danbury Eye Physicians & Surgeons, PCLead Sponsor
Stephen A Mathias, MD, MPHPrincipal InvestigatorDanbury Eye Physicians & Surgeons, PC
~3 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top